We use cookies to improve your experience on our site and to analyze traffic. By clicking "Accept", you consent to our use of cookies. Learn more.

Meet Nova at the MIDD Summit in Boston, Nov 18–19Join our talk with GSK on day oneSee our talk
1/2
All news & conferences
Press release April 2025 Lyon, France and Tokyo, Japan

Nova collaborates with Fujitsu to transform clinical trials through AI-powered simulations

Nova In Silico, a leader in biosimulation, model-informed drug development, pharmacometrics, and quantitative systems pharmacology, has partnered with Fujitsu, a global technology and AI innovator, to transform clinical trial simulations and accelerate drug development through AI-driven modeling solutions.

Millions of patients around the world await new treatments, but clinical trials remain expensive and slow. Trials for rare and pediatric diseases are especially difficult because of complex designs and recruitment challenges. Nova and Fujitsu are working together to improve clinical trial design and predictive modeling, helping pharmaceutical companies optimize protocols, reduce development timelines, and improve patient outcomes.

Jinkō, Nova's platform, enables pharmaceutical companies to create and test virtual patient populations, simulate real-world clinical scenarios, and refine trial protocols before patient recruitment. Through this partnership, Fujitsu will support Jinkō's expansion in Japan and beyond, integrating AI and computing technologies to improve modeling accuracy and scalability.

Nova and Fujitsu will also jointly develop Japan-specific virtual populations using real-world health data available through Fujitsu's Healthy Living Platform, a cloud infrastructure designed to collect, integrate, and analyze healthcare information.

“Clinical trials are at a turning point, and AI-powered simulations can transform how therapies are developed. Our partnership with Fujitsu marks an important step in bringing mechanistic modeling and predictive analytics to the forefront of clinical trial optimization, ultimately benefiting patients and healthcare providers worldwide.”

Grégoire Boutonnet and Frédéric Cogny, co-CEOs of Nova In Silico

“Fujitsu is committed to addressing the pressing challenge of drug loss in Japan by accelerating the digitization of clinical trials and transforming how pharmaceutical companies conduct trials. By combining Nova's expertise in quantitative pharmacology with Fujitsu's AI-driven analytics and data processing, we will create an ecosystem that enhances trial efficiency, increases success rates, and speeds up the delivery of life-saving therapies.”

Tatsuki Araki, Head of Healthy Living at Fujitsu

About Nova In Silico

Nova In Silico provides computational modeling and simulation solutions for the life sciences industry. Its Jinkō platform enables pharmaceutical and biotech companies to conduct virtual clinical trials, optimize drug development strategies, and enhance translational research. Nova's mission is to bridge the gap between mechanistic modeling and clinical decision-making to improve patient outcomes worldwide.

About Fujitsu

Fujitsu is a global technology leader committed to building trust in society through innovation. With expertise spanning AI, computing, data security, and cloud technologies, Fujitsu delivers transformative solutions across industries, including healthcare and life sciences. Through its Fujitsu Uvance initiative, the company works to advance sustainability and improve quality of life through digital transformation.